Talquetamab

Definition

A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.

Also known as Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, GPRC5D x CD3 Bispecific Antibody JNJ-64407564, GPRC5D x CD3 DuoBody Antibody JNJ-64407564, GPRC5D/CD3 DuoBody Antibody JNJ-64407564, Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564, JNJ 64407564, JNJ-64407564, JNJ64407564, TALQUETAMAB, Talquetamab-tgvs — per NCIT

Also identified as

• ATC L01FX29 per RXNORM
• NCIT NCIT:C171840 per NCIT
• SCTID 1363065009 per RXNORM
• UNII 4W3KFI3TN3 per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.